BioVersys AG | Finanzwire

BRIEF

published on 03/16/2026 at 07:05, 1 day 10 hours ago

BioVersys Gets FDA Nod for BV100 Phase 3 Trial for Pneumonia

FDA Approval Phase 3 Trial BV100 BioVersys CRAB Infections
PRESS RELEASE

published on 03/16/2026 at 07:00, 1 day 10 hours ago

BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
BioVersys receives US FDA green light for BV100 HABP/VABP Phase 3 pivotal trial start to address CRABC infections in hospital-acquired bacterial pneumonia. A significant step in developing novel antibacterial products for MDR bacteria

Phase 3 BV100 BioVersys US FDA CRABC
BRIEF

published on 03/12/2026 at 07:05, 5 days 10 hours ago

BioVersys Initiates Phase 2b Trial for AlpE in Tuberculosis Treatment

Drug Resistance BioVersys Tuberculosis AlpE Clinical Trial UNITE4TB
PRESS RELEASE

published on 03/12/2026 at 07:00, 5 days 10 hours ago

BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis
BioVersys announces the first patient dosed in a Phase 2b clinical trial of AlpE for pulmonary tuberculosis, collaborating with GSK under UNITE4TB project. Results expected by end of 2027

GSK Phase 2b BioVersys AlpE Pulmonary Tuberculosis
BRIEF

published on 03/05/2026 at 07:05, 12 days 10 hours ago

BioVersys Set to Announce 2025 Financial Results and Business Update

Financial Results Conference Call Strategic Outlook Antibacterial Products BioVersys
PRESS RELEASE

published on 03/05/2026 at 07:00, 12 days 10 hours ago

BioVersys to Report its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call
BioVersys AG to report Full Year 2025 financial results, provide business update, and host conference call on March 18, 2026. Focus on antibacterial products for MDR bacteria

Financial Results BioVersys AG Antibacterial Products MDR Bacteria Full Year 2025
BRIEF

published on 03/04/2026 at 07:05, 13 days 10 hours ago

BioVersys Publishes BV100 Phase 1 Clinical Data

Clinical Trial BV100 BioVersys Pharmacokinetics Acinetobacter Baumannii
PRESS RELEASE

published on 03/04/2026 at 07:00, 13 days 10 hours ago

BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy
BioVersys announces publication of BV100 Phase 1 clinical data in Journal of Antimicrobial Agents and Chemotherapy

Clinical Data Phase 1 BV100 BioVersys Antibacterial
BRIEF

published on 02/19/2026 at 07:22, 26 days 10 hours ago

BioVersys Achieves Breakthrough in Tuberculosis Treatment

Phase 2A Trial Drug Resistance Tuberculosis Alpibectir Collaborative Research
PRESS RELEASE

published on 02/19/2026 at 07:17, 26 days 10 hours ago

BioVersys and partners’ phase 2a tuberculosis trial results published in New England Journal of Medicine
BioVersys and partners demonstrate promising results with AlpE in Phase 2a tuberculosis trial, published in New England Journal of Medicine. AlpE shows potential in treating drug-resistant tuberculosis

Clinical Trial Drug Resistance BioVersys Tuberculosis AlpE

1 2 ... 6

Published on 03/17/2026 at 13:30, 3 hours 57 minutes ago

Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026
Published on 03/17/2026 at 13:30, 3 hours 57 minutes ago

Namibia Critical Metals Welcomes Toyota Tsusho as Strategic Partner in the Lofdal Heavy Rare Earths Project
Published on 03/17/2026 at 13:00, 4 hours 27 minutes ago

Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland
Published on 03/17/2026 at 13:00, 4 hours 27 minutes ago

High-Resolution Airborne Survey Completed at Music Valley HREE Project
Published on 03/17/2026 at 12:30, 4 hours 57 minutes ago

Revival Gold Targets Underground Resource Growth With Drilling at Beartrack-Arnett Gold Project in Idaho

View all ACCESSWIRE

Published on 03/17/2026 at 15:30, 1 hour 56 minutes ago

Original-Research: Desert Gold Ventures Inc. (von GBC AG): Buy
Published on 03/17/2026 at 15:19, 2 hours 8 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC
Published on 03/17/2026 at 15:18, 2 hours 9 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Senior PLC
Published on 03/17/2026 at 15:17, 2 hours 10 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders PLC
Published on 03/17/2026 at 15:16, 2 hours 11 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Ltd

View all EQS

Published on 03/17/2026 at 07:00, 10 hours 27 minutes ago

Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 23 hours 27 minutes ago

Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 23 hours 29 minutes ago

Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 23 hours 30 minutes ago

Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:45, 23 hours 42 minutes ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News